NSCLC Daily News from ASCO 2014: May 30, 2014 – Preview of Key Topics

The presentations at ASCO 2014 will be providing a comprehensive review of important research developments in non–small-cell lung cancer (NSCLC), one of the most rapidly evolving fields in cancer medicine. Moreover, many of the presentations will help attendees refine the nuances of their clinical decision-making in treating patients with locally advanced and metastatic NSCLC. Here is our Top 10 List that includes many of the key topics in NSCLC to be discussed during ASCO 2014:

• Indications for molecular testing and utilization of molecular biomarkers in metastatic disease
• New developments in immune checkpoint therapy—the role of PD-1 inhibitors
• Optimal first-line therapy for patients with EGFR mutations—new data with existing and emerging agents, especially for patients with acquired resistance to EGFR inhibitors
• Evolving concepts in the use of anti-EGFR adjuvant therapy in surgically resected NSCLC
• Effectiveness of second-generation ALK inhibitors
• New data with anti-HER3 therapy in advanced NSCLC
• Emerging EGFR inhibitors, used with or without chemotherapy, in squamous NSCLC
• New approaches to MET-positive, advanced-stage NSCLC
• Benefits and drawbacks of first-line concurrent versus sequential anti-EGFR/chemotherapy combinations
• New molecular entities for second- or third-line therapy in locally advanced or metastatic NSCLC—the role of pan-HER inhibitors

Be sure to read the daily ASCO Conference E-Highlight Reports to learn the details of these and other important, potentially practice-changing advances in the management of patients with NSCLC. Moreover, the key theme for ASCO 2014 is “Science and Society,” in which the role of value in cancer care of NSCLC will be integrated into presentations, as well as featured separately at unique stand-alone sessions on value-based issues in oncology. Whenever appropriate, we will include concepts regarding value-based care in NSCLC therapy in our reports.